Skip to Content

Poliovirus Vaccine, Inactivated Dosage

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Poliomyelitis Prophylaxis

Unvaccinated adults:
Two 0.5 mL doses, administered IM or subcutaneously, given at a 1 to 2 month interval and a third dose given 6 to 12 months later.
If less than 3 months but more than 2 months are available before protection is needed, three doses should be given at least a month apart.
If only 1 to 2 months are available, 2 doses should be given at least a month apart. If less than 1 month is available, 1 dose is recommended.

Incompletely vaccinated adults:
(Who are at increased risk for poliovirus exposure who have had at least one dose of oral polio vaccine, fewer than 3 doses of conventional poliovirus vaccine inactivated or a combination of the two totaling fewer than 3 doses)
At least 1 dose of poliovirus vaccine. Additional doses necessary to complete the series should be given if time permits.

Completely vaccinated adults:
(Who are at increased risk for poliovirus exposure)
1 dose.

The preferred injection site is in the deltoid area.

Usual Pediatric Dose for Poliomyelitis Prophylaxis

Primary vaccination series:
>= 6 weeks:
Three 0.5 mL doses administered IM or subcutaneously, preferably 8 or more weeks apart and usually at ages 2, 4, and 6 to 18 months. Do not give more frequently than 4 weeks apart. The preferred injection site is into the midlateral aspect of the thigh. A booster dose should be administered at 4 to 6 years.

Incompletely vaccinated children and adolescents:
Administer sufficient doses to complete the series. Interruption of the recommended schedule with a delay between doses does not interfere with final immunity. There is no need to start either series over again, regardless of the time elapsed between doses.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended


Poliovirus vaccine is contraindicated in patients with a history of hypersensitivity to neomycin, streptomycin, polymyxin B, 2-phenoxyethanol, and formaldehyde. Trace amounts of these substances may be present in the vaccine. The syringe case and needle cover contain natural latex rubber.

Anaphylaxis may occur, even in patients with no previous hypersensitivity to the vaccine ingredients. Epinephrine and other medications and equipment should be readily available to treat anaphylactic or severe allergic reactions.

Further doses of vaccine should not be given if anaphylaxis or anaphylactic shock occurs within 24 hours after administration of a dose.

Vaccination should be deferred in patients with an acute febrile illness. Deferral is not necessary in patients with minor illnesses such as an upper respiratory tract infection, with or without a low-grade fever. The vaccine is not contraindicated in HIV-infected patients.

Systemic adverse events have occurred in infants receiving poliovirus vaccine concurrently with DTP vaccine, which were similar to adverse events with DTP vaccine alone.

The expected immune response may not occur in immunosuppressed patients.

Injection into a blood vessel should be avoided.

Any allergic or unusual adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 (USA).


No adjustment recommended

Other Comments

The vaccine should be stored under refrigeration. It should not be frozen.